Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment

Phase 1 Completed 41 enrolled Millennium Pharmaceuticals, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to characterize the single-dose pharmacokinetic (PK) parameters of ixazomib (MLN9708) in cancer participants with either normal renal function or severe renal impairment (RI), including participants with end-stage renal disease (ESRD).

Timeline

Start: 2013-09-16
Primary completion: 2015-03-03
Completion: 2016-11-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ixazomib	Unknown	2.3 mg	Oral
Subject	Ixazomib	Unknown	3 mg	Oral
Subject	Ixazomib	Unknown	4 mg	Oral

Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment

Summary

Timeline

Drugs

Indications